Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 165 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: liraglutide Clear all
Completed Phase 3 Interventional Results available

Liraglutide In Overweight Patients With Type 1 Diabetes

NCT01753362
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
liraglutide, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 22, 2026, 5:05 PM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

NCT02299388
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
Interventions
Liraglutide or Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

RISE Adult Medication Study

NCT01779362
View directory record Official record
Conditions
Prediabetes, Type 2 Diabetes
Interventions
Metformin, Liraglutide, Glargine, Placebo
Drug
Lead sponsor
RISE Study Group
Network
Eligibility
20 Years to 65 Years
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

NCT01516476
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO6807952, liraglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Liraglutide in Type 1 Diabetes

NCT01722240
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Liraglutide 1.8mg, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

NCT02420262
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
50
States / cities
Tuscumbia, Alabama • Anaheim, California • Bermuda Dunes, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

NCT01511185
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

NCT02014740
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Liraglutide, Metformin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

NCT03235050
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Liraglutide Hospital Discharge Trial

NCT01919489
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide + OADs, Glargine + OADs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

NCT01117350
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Liraglutide, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

NCT00620282
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, glimepiride
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Jul 22, 2026, 5:05 PM EDT
Completed No phase listed Observational

Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data

NCT05162183
View directory record Official record
Conditions
Diabetes
Interventions
Glimepiride, Liraglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
3,474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

NCT02963935
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo, CMS Intensive Behavior Therapy
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Jacksonville, Florida • Plantation, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

NCT02773368
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Glendale, Arizona • La Jolla, California • Mission Viejo, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Jul 22, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

NCT07029009
View directory record Official record
Conditions
Maturity Onset Diabetes of the Young
Interventions
Liraglutide
Drug
Lead sponsor
Mansa
Other
Eligibility
10 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

NCT00943501
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
14
States / cities
Cypress, California • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Liraglutide Effects on Epicardial Fat Inflammatory Genes

NCT03260881
View directory record Official record
Conditions
Type2 Diabetes, Coronary Artery Disease
Interventions
Liraglutide Pen Injector [Victoza], matching liraglutide-placebo pre-filled pens
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

NCT02298192
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
40
States / cities
Hamilton, Alabama • Chandler, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 22, 2026, 5:05 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

NCT04575844
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Liraglutide, Exercise training, Liraglutide + Exercise training
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

NCT05579249
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT02205528
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus Type 2
Interventions
Liraglutide, Metformin, Placebo, NNC0090-2746
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jul 22, 2026, 5:05 PM EDT
Not listed Phase 4 Interventional

Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes

NCT02344186
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 22, 2026, 5:05 PM EDT